Xtant Medical Holdings Inc (XTNT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xtant Medical Holdings Inc (XTNT) has a cash flow conversion efficiency ratio of 0.106x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.38 Million) by net assets ($50.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xtant Medical Holdings Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Xtant Medical Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read XTNT total debt and obligations for a breakdown of total debt and financial obligations.
Xtant Medical Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xtant Medical Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ktcs corporation
KO:058850
|
0.040x |
|
Bina Puri Holdings Bhd
KLSE:5932
|
-0.676x |
|
Solborn Inc
KQ:035610
|
-0.027x |
|
OptimumBank Holdings, Inc.
NYSE MKT:OPHC
|
0.052x |
|
Sypris Solutions Inc
NASDAQ:SYPR
|
-0.063x |
|
TECO Image Systems Co Ltd
TWO:5438
|
-0.017x |
|
NextSource Materials Inc
TO:NEXT
|
-0.291x |
|
Forian Inc
NASDAQ:FORA
|
0.108x |
Annual Cash Flow Conversion Efficiency for Xtant Medical Holdings Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Xtant Medical Holdings Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see XTNT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $50.95 Million | $12.55 Million | 0.246x | +188.93% |
| 2024-12-31 | $42.96 Million | $-11.90 Million | -0.277x | -49.43% |
| 2023-12-31 | $51.35 Million | $-9.52 Million | -0.185x | -18.55% |
| 2022-12-31 | $34.17 Million | $-5.34 Million | -0.156x | -1199.56% |
| 2021-12-31 | $30.88 Million | $439.00K | 0.014x | +128.22% |
| 2020-12-31 | $14.51 Million | $-731.00K | -0.050x | -639.08% |
| 2019-12-31 | $-44.20 Million | $-413.00K | 0.009x | +133.74% |
| 2018-12-31 | $-43.77 Million | $1.21 Million | -0.028x | -399.22% |
| 2017-12-31 | $-58.70 Million | $-543.18K | 0.009x | -99.55% |
| 2016-12-31 | $-7.07 Million | $-14.41 Million | 2.037x | +298.69% |
| 2015-12-31 | $8.88 Million | $-9.10 Million | -1.025x | -208.83% |
| 2014-12-31 | $-7.77 Million | $-7.32 Million | 0.942x | -35.61% |
| 2013-12-31 | $-3.84 Million | $-5.62 Million | 1.463x | +157.37% |
| 2012-12-31 | $4.23 Million | $-10.79 Million | -2.550x | -90.53% |
| 2011-12-31 | $5.50 Million | $-7.36 Million | -1.338x | -109.90% |
| 2010-12-31 | $-619.24K | $-8.37 Million | 13.520x | +1825.08% |
| 2009-12-31 | $4.68 Million | $-3.67 Million | -0.784x | -123.00% |
| 2008-12-31 | $11.34K | $38.64K | 3.407x | -- |
About Xtant Medical Holdings Inc
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validate… Read more